http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#Head http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#assertion http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#provenance http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#pubinfo http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#assertion http://purl.obolibrary.org/obo/DOID_8469 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8469 http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06614 http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association http://www.w3.org/2000/01/rdf-schema#label rapivab is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days 1 limitations of use efficacy based on clinical trials in which the predominant influenza virus type was influenza a a limited number of subjects infected with influenza b virus were enrolled 1 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 efficacy could not be established in patients with serious influenza requiring hospitalization 1 limitations of use efficacy of rapivab is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza a virus a limited number of subjects infected with influenza b virus were enrolled influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rapivab see microbiology 12 4 the efficacy of rapivab could not be established in patients with serious influenza requiring hospitalization see clinical studies 14 3 http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06614 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#provenance http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#pubinfo http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#sig http://purl.org/nanopub/x/hasSignature eWwpYI95pbaj2XO1rhqPfRRg5/MmSlZ57ZlVJ5/jktBQN2anQo/uTsyUuNsmBecR4TQ0FbxVTTIX9nZ3KBnUb/wLoPmwR/BwHszv8SQjbLd/JRkXI0qLUGrzDJgjb2OGDHkRVLEel/W7BGSNASIUvXmZiV4Nh44hYApAAPl1MW8= http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://purl.org/dc/terms/created 2021-07-03T14:42:36.110+02:00 http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAqC1DEyLf_lrKx1-WAf1qpcac57MnGuSMTemjF8OEgow https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs